- In March 2025, aTyr Pharma, a clinical-stage biotechnology company, announced a fourth positive safety review from an independent data and safety monitoring board (DSMB) for its Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis. The DSMB recommended continuation of the study without modifications, reinforcing confidence in the drug's favorable safety profile. This is a significant step towards positioning efzofitimod as a potential chronic, corticosteroid-sparing maintenance therapy for pulmonary sarcoidosis. Topline results from this global study are anticipated in the third quarter of 2025
- In March 2025, Xentria, Inc. announced significant progress in its XTMAB-16 study for pulmonary sarcoidosis, confirming the successful enrollment of patients for the dose-ranging study. XTMAB-16 is a novel anti-TNF-α monoclonal antibody being developed as a potential new biologic for pulmonary sarcoidosis. This advancement underscores Xentria's commitment to addressing the unmet need for targeted therapies in sarcoidosis, with the next phase of investigation, including further patient screening, anticipated to begin in Fall 2025.
- In May 2024, The Foundation for Sarcoidosis Research (FSR) launched the Coalition for Clinical Trial Equity (CTCTE) to address barriers faced by Black patients in participating in clinical trials for sarcoidosis. This initiative aims to increase diversity in trials, recognizing the disproportionate impact of sarcoidosis on Black communities and the need for inclusive research to develop more effective treatments for all patients. This highlights a critical effort to improve drug development processes by ensuring diverse patient representation.
- In April 2024, The Foundation for Sarcoidosis Research (FSR) partnered with Walgreens in Alabama to boost sarcoidosis awareness and promote spring vaccine education for April Awareness Month. This collaboration exemplifies ongoing efforts by patient advocacy groups to increase public and medical community understanding of sarcoidosis, which can lead to earlier diagnosis and, consequently, greater demand for effective drug therapies
- In January 2024, A research team led by Georg Stary at the Medical University of Vienna and CeMM (Research Center for Molecular Medicine of the Austrian Academy of Sciences) identified a new therapeutic approach for sarcoidosis, specifically demonstrating success in treating granulomas in the skin.
